Sit Investment Associates Inc. lowered its position in Pfizer, Inc. (NYSE:PFE) by 10.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,050,665 shares of the biopharmaceutical company’s stock after selling 118,345 shares during the period. Pfizer makes up approximately 0.9% of Sit Investment Associates Inc.’s investment portfolio, making the stock its 24th largest position. Sit Investment Associates Inc.’s holdings in Pfizer were worth $35,943,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the company. Perennial Advisors LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $209,000. LVW Advisors LLC increased its position in shares of Pfizer by 2.1% in the fourth quarter. LVW Advisors LLC now owns 82,620 shares of the biopharmaceutical company’s stock worth $2,683,000 after buying an additional 1,701 shares in the last quarter. First Capital Advisors Group LLC. acquired a new position in shares of Pfizer during the fourth quarter worth about $921,000. RidgeWorth Capital Management LLC increased its position in shares of Pfizer by 3.1% in the fourth quarter. RidgeWorth Capital Management LLC now owns 1,960,889 shares of the biopharmaceutical company’s stock worth $63,690,000 after buying an additional 58,133 shares in the last quarter. Finally, Redmond Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $398,000. Institutional investors own 69.95% of the company’s stock.
Shares of Pfizer, Inc. (PFE) opened at 33.54 on Friday. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $37.39. The firm has a market cap of $200.16 billion, a PE ratio of 28.23 and a beta of 1.01. The firm’s 50-day moving average price is $33.20 and its 200 day moving average price is $33.25. Pfizer also saw some unusual options trading on Tuesday. Stock investors acquired 21,983 put options on the stock. This represents an increase of 351% compared to the typical volume of 4,871 put options.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.02. The company had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. Pfizer’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS. On average, equities research analysts forecast that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.82%. Pfizer’s payout ratio is 108.48%.
TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (PFE) Stake Cut by Sit Investment Associates Inc.” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/07/21/pfizer-inc-pfe-stake-cut-by-sit-investment-associates-inc.html.
A number of equities analysts have issued reports on PFE shares. Societe Generale reiterated a “neutral” rating and set a $36.00 price target on shares of Pfizer in a research report on Thursday, March 23rd. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price target on shares of Pfizer in a research report on Friday, March 24th. Morgan Stanley reiterated a “neutral” rating and set a $38.00 price target on shares of Pfizer in a research report on Thursday, April 6th. Jefferies Group LLC reiterated a “neutral” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $37.68.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
